Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy.
BACKGROUND
Testosterone is needed for normal male development, muscle strength, bone mineralization, hematopoietic function, and sexual and reproductive functions. The main purpose of androgen deprivation therapy in prostate cancer is to reduce tumor progression, but therapy is often accompanied by significant adverse effects.


OBJECTIVE
This study aimed to determine the effects of androgen deprivation therapy on body composition and resting metabolic rate in patients with prostate cancer.


METHODS
A prospective study was performed to evaluate the body composition of 16 elderly males (aged 63-96; median age 71) with prostate cancer scheduled for orchiectomy, one year before and after surgery. Body composition was measured by DEXA, and energy expenditure, fat and carbohydrate oxidation were measured by indirect calorimetry.


RESULTS
Body weight (p=0.01), lean mass (p=0.004), and lipid oxidation (p=0.001) decreased significantly. Carbohydrate oxidation (p=0.02), FSH (p=0.0001) and LH (p=0.0001) levels increased significantly. Changes in fat mass (p=0.06) and bone mineral density (p=0.48) were not significant.


CONCLUSIONS
After 12 months of androgen deprivation therapy, elderly men with metastatic prostate cancer exhibit a decline in lean body mass and lipid oxidation, together with increased carbohydrate oxidation.
Reis
Cristiana
C
Department of Geriatric and Gerontology, Department of Endocrinology and Metabolism and Department of Urology, Faculdade de Medicina da Universidade de São Paulo, São Paulo/SP, Brazil. vitalita@uol.com.br
Liberman
Sami
S
Pompeo
Antonio Carlos
AC
Srougi
Miguel
M
Halpern
Alfredo
A
Filho
Wilson Jacob
WJ
D000368:Aged; D000369:Aged, 80 and over; D001823:Body Composition / Q000502:physiology*; D050260:Carbohydrate Metabolism / Q000502:physiology*; D004734:Energy Metabolism / Q000502:physiology*; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011184:Postoperative Period; D011300:Preoperative Care; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000601:surgery*; D018709:Statistics, Nonparametric
CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1
10200775
J Clin Endocrinol Metab. 2005 Feb;90(2):657-60
15562007
Clin Physiol. 1991 Jul;11(4):331-41
1914437
Circulation. 1988 Sep;78(3):539-45
3409497
Urology. 2008 Apr;71(4):735-9
18279933
J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65
8954042
J Gerontol A Biol Sci Med Sci. 2000 Dec;55(12):M757-60
11129399
J Clin Endocrinol Metab. 1998 Jun;83(6):1886-92
9626114
Urology. 2001 Aug;58(2 Suppl 1):101-7
11502461
BJU Int. 2008 Jul;102(1):44-7
18336606
J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
11836291
Metabolism. 1988 Mar;37(3):287-301
3278194
J Clin Endocrinol Metab. 2001 Feb;86(2):724-31
11158037
Crit Rev Oncol Hematol. 2008 Nov;68(2):172-7
18706829
Endocrinology. 1990 Feb;126(2):1229-34
2153523
J Urol. 2008 Feb;179(2):414-23
18076933
J Urol. 2007 Jan;177(1):17-24
17161994
J Clin Endocrinol Metab. 2001 Sep;86(9):4261-7
11549659
Diabetes. 1994 Feb;43(2):212-9
8288045